Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Cilazapril Monohydrate (Justor) 是一种血管紧张素转化酶抑制剂,能够作用于高血压和充血性心力衰竭的研究。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
25 mg | ¥ 9,930 | 4-6周 | ||
1 mL * 10 mM (in DMSO) | ¥ 7,480 | 4-6周 |
产品描述 | Cilazapril Monohydrate (Justor) is an angiotensin-converting enzyme (ACE) inhibitor used for the treatment of hypertension and congestive heart failure. |
体外活性 | BML-190 has 50-fold selectivity for CB2 receptors over CB1 receptors. In HEK-293 cells stably expressing the human CB2 receptor, BML-190 potentiates the forskolin-stimulated accumulation of cAMP. BML-190 reduces the basal levels of inositol phosphate production in cells expressing the CB2 receptor. 10 μM of BML-190 decreases inositol phosphates accumulation by 38%. [1] BML-190 is an aminoalkylindole. BML-190 is found to yield at least 15 metabolic products. [2] BML-190 diminishes LPS-induced NO and IL-6 production in a concentration-dependent manner. BML-190 also inhibits LPS-induced PGE2 production and COX-2 induction. [3] |
体内活性 | Cilazapril (1 mg/kg, daily) tends to decrease and the higher dose (10 mg/kg, daily) significantly decreases systolic blood pressure (SBP) in subtotal nephrectomized rats. Cilazapril attenuates the further development of protein uria in a dose-dependent manner in subtotal nephrectomized rats. Cilazapril attenuates the increase in plasma fibrinogen concentration and serum albumin concentration in a dose-dependent manner. Cilazapril reduces serum MCP-1 concentration in the nephrectomized rats. Cilazapril decreases hepatic fibrinogen synthesis through the alleviation of the local inflammatory process and the improvement of hypoalbuminemia. [1] Cilazapril normalizes systolic arterial pressure to 121 mm Hg (SD) in the treated SHR-SP rats. Cilazapril decreases systolic arterial pressure to a nearly normal level and prevents hypertensive retinal vascular changes, probably by improving endothelial function. [2] Cilazapril results in a marked decrease in the Kd of the renal arginine vasopressin (AVP) receptor and an increase in the plasma AVP level in the spontaneously hypertensive rat. [3] Cilazapril exerts a rapid, complete, and persistent antihypertensive effect in the spontaneously hypertensive rats (SHR) in vivo but has no effect on SAP in the normotensive Sprague-Dawley rat. Cilazapril treatment depresses heart performance (28-35%) in SHR but has no effect in the Sprague-Dawley rats. [4] Cilazapril decreases blood pressure to control values and reduces HW:BW in hyperthyroid rats. [5] |
别名 | Ro 31-2848 monohydrate, Justor, 西拉普利, 西拉普利水合物 |
分子量 | 435.51 |
分子式 | C22H31N3O5·H2O |
CAS No. | 92077-78-6 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Ethanol: 81 mg/mL (186 mM)
H2O: <1 mg/mL
DMSO: 81 mg/mL (186 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
Ethanol / DMSO | 1 mM | 2.2962 mL | 11.4808 mL | 22.9616 mL | 57.404 mL |
5 mM | 0.4592 mL | 2.2962 mL | 4.5923 mL | 11.4808 mL | |
10 mM | 0.2296 mL | 1.1481 mL | 2.2962 mL | 5.7404 mL | |
20 mM | 0.1148 mL | 0.574 mL | 1.1481 mL | 2.8702 mL | |
50 mM | 0.0459 mL | 0.2296 mL | 0.4592 mL | 1.1481 mL | |
100 mM | 0.023 mL | 0.1148 mL | 0.2296 mL | 0.574 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Cilazapril Monohydrate 92077-78-6 Endocrinology/Hormones RAAS Angiotensin-converting Enzyme (ACE) Ro 31-2848 monohydrate Justor 西拉普利 Inhibitor Ro 31-2848 Monohydrate 西拉普利水合物 Ro 31-2848 inhibit Cilazapril inhibitor